Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness.

about

Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness.

Item

http://www.wikidata.org/entity/Q41990860

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Addition of a renin-angiotensi ...... meliorates arterial stiffness.

@en

type

Item

label

Addition of a renin-angiotensi ...... meliorates arterial stiffness.

@en

prefLabel

Addition of a renin-angiotensi ...... meliorates arterial stiffness.

@en

P1476

Addition of a renin-angiotensi ...... meliorates arterial stiffness.

@en

P2093

Junichi Yamazaki

http://www.w3.org/2001/XMLSchema#string

Muneyasu Kawasaki

http://www.w3.org/2001/XMLSchema#string

Osamu Hirashima

http://www.w3.org/2001/XMLSchema#string

Shinji Hisatake

http://www.w3.org/2001/XMLSchema#string

Shunsuke Kiuchi

http://www.w3.org/2001/XMLSchema#string

Takanori Ikeda

http://www.w3.org/2001/XMLSchema#string

Takayuki Kabuki

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

Hypertension management 2011: optimal combination therapy.

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.

Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke.

The risk of myocardial infarction associated with antihypertensive drug therapies.

Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and c

Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.

Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial.

Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.

P304

97-102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CPAA.S81880

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26487804

http://www.w3.org/2001/XMLSchema#string

P932

4607055

http://www.w3.org/2001/XMLSchema#string